Channels - A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection :: FRELIP Discovery

Similar Items: A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection

Quick Look
The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer
Quick Look
Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis
Quick Look
Community Experience With Pediatric‐Inspired Regimens for Acute Lymphoblastic Leukemia in Adolescent and Young Adults
Quick Look
Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer
Quick Look
Chemo‐Immunotherapy, a Combination Approach for the Treatment of HER2‐Positive Breast Cancer in a Mouse Model
Quick Look
Postoperative Complications Following Neoadjuvant Therapy Across Different Oncoplastic Breast Surgery Techniques: A Retrospective Comparative Study in Breast Cancer Patients
Quick Look
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
Quick Look
Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer
Quick Look
HER2 Expression and Axillary Metastasis in Treatment-Naïve Early Breast Cancer
Quick Look
Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence
Quick Look
HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies
Quick Look
Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer
Quick Look
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
Quick Look
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
Quick Look
HER2 Overexpression in Invasive Breast Carcinoma in the Democratic Republic of Congo and its Association with Selected Clinicopathological Characteristics
Quick Look
Integration of Raman Spectroscopy and Metabolomics for Early Breast Cancer Detection and Classification
Quick Look
Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices
Quick Look
Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data
Quick Look
Identification of an Immune Cell Gene Signature for Predicting Response and Prognosis in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
Quick Look
Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia
Quick Look
Microenvironmental Cues That Regulate Cancer Cell Dormancy in Estrogen‐Receptor Positive and Triple‐Negative Breast Cancer Cell Lines
Quick Look
Vactosertib enhances radiotherapy efficacy by modulating radiation-induced tumor microenvironment remodeling in breast cancer
Quick Look
MRI‐Based DeltaHabitat Radiomic Model Predicts Pathological Complete Response in Oral Cavity Cancer Treated With Neoadjuvant Chemoimmunotherapy
Quick Look
A Systematic Review on Dostarlimab-gxlyin in the Treatment of Rectal Cancer: Efficacy, Safety, and Future Directions